MQ:NASDAQMarqeta, Inc. Analysis
Data as of 2026-04-18 - not real-time
Latest Price
Risk Level: Medium
Executive Summary
Marqeta’s stock is trading at $4.39, comfortably above its 20‑day (4.075) and 50‑day (4.060) simple moving averages but still below the 200‑day average (4.931), suggesting short‑term bullish momentum within a longer‑term downtrend. The RSI of 63.8 and a bullish MACD histogram (+0.036) reinforce this near‑term upside, while the price sits near the technical resistance of $4.42 and above the support level of $3.82. Revenue is expanding at a brisk 26.7% year‑over‑year with a robust 70% gross margin, yet operating margins remain negative (‑7.6%) and the company posts a modest loss per share (‑$0.03). Strong cash balances ($771.9 M) and positive free cash flow ($138.9 M) offset the low debt load, but the forward P/E of 62.7 versus the industry average of 36.7 signals an overvalued valuation. Analysts forecast a modest upside of ~17% (target median $5.00) and the DCF model implies a fair value near $13.4, creating a wide valuation spread. Upcoming Q1 2026 earnings on May 5, an insider sale of 5,055 shares, and JPMorgan’s recent “overweight” rating with a $6 price target add short‑term catalysts that could swing sentiment in this high‑volatility (38.8% 30‑day) environment.
Market Outlook
Short Term
< 1 yearKey Factors
- Bullish MACD and RSI indicate near‑term momentum
- Price approaching technical resistance at $4.42
- Upcoming Q1 earnings release adds catalyst risk
Medium Term
1–3 yearsKey Factors
- Strong revenue growth and high gross margin
- Positive free cash flow and ample cash reserves
- Analyst target median price of $5.00 suggests ~17% upside
Long Term
> 3 yearsKey Factors
- Persistent operating losses and high forward P/E
- Competitive fintech landscape and regulatory exposure
- Need for sustained profitability to justify valuation
Key Metrics & Analysis
Financial Health
Technical Analysis
Valuation
Risk Assessment
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.